

James Brian Byrd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2638328/publications.pdf>

Version: 2024-02-01

73
papers

12,210
citations

236925

25
h-index

91884

69
g-index

83
all docs

83
docs citations

83
times ranked

18284
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1535750.	12.2	6,961
2	A Controlled Trial of Renal Denervation for Resistant Hypertension. <i>New England Journal of Medicine</i> , 2014, 370, 1393-1401.	27.0	1,848
3	EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. <i>Nature Methods</i> , 2017, 14, 228-232.	19.0	886
4	Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12093.	12.2	182
5	Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. <i>JAMA Network Open</i> , 2021, 4, e2116901.	5.9	179
6	Privacy-Preserving Generative Deep Neural Networks Support Clinical Data Sharing. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005122.	2.2	172
7	Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, 725-737.	1.9	135
8	Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema. <i>Hypertension</i> , 2008, 51, 141-147.	2.7	128
9	Characterizing Long COVID: Deep Phenotype of a Complex Condition. <i>EBioMedicine</i> , 2021, 74, 103722.	6.1	127
10	Primary Aldosteronism. <i>Circulation</i> , 2018, 138, 823-835.	1.6	113
11	Data quality of an electronic health record tool to support VA cardiac catheterization laboratory quality improvement: The VA Clinical Assessment, Reporting, and Tracking System for Cath Labs (CART) program. <i>American Heart Journal</i> , 2013, 165, 434-440.	2.7	97
12	Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans. <i>Annals of Internal Medicine</i> , 2021, 174, 289-297.	3.9	79
13	Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 714-716.	4.5	74
14	Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism. <i>Clinical Endocrinology</i> , 2017, 87, 665-672.	2.4	68
15	Responsible, practical genomic data sharing that accelerates research. <i>Nature Reviews Genetics</i> , 2020, 21, 615-629.	16.3	66
16	Separation, characterization, and standardization of extracellular vesicles for drug delivery applications. <i>Advanced Drug Delivery Reviews</i> , 2021, 174, 348-368.	13.7	66
17	Summary of the ISEV workshop on extracellular vesicles as disease biomarkers, held in Birmingham, UK, during December 2017. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1473707.	12.2	60
18	Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 403-408.	2.9	48

#	ARTICLE	IF	CITATIONS
19	Combination therapy as initial treatment for newly diagnosed hypertension. <i>American Heart Journal</i> , 2011, 162, 340-346.	2.7	47
20	Acute increase in blood pressure during inhalation of coarse particulate matter air pollution from an urban location. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 133-139.e4.	2.3	40
21	Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 487-492.	3.6	40
22	Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1381-1387.	5.7	39
23	Bradykinin Type 2 Receptor BE1 Genotype Influences Bradykinin-Dependent Vasodilation During Angiotensin-Converting Enzyme Inhibition. <i>Hypertension</i> , 2008, 51, 454-459.	2.7	38
24	Hypertension Hot Potato – Anatomy of the Angiotensin-Receptor Blocker Recalls. <i>New England Journal of Medicine</i> , 2019, 380, 1589-1591.	27.0	37
25	Reach Out Churches: A Community-Based Participatory Research Pilot Trial to Assess the Feasibility of a Mobile Health Technology Intervention to Reduce Blood Pressure Among African Americans. <i>Health Promotion Practice</i> , 2018, 19, 495-505.	1.6	32
26	Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. <i>European Heart Journal</i> , 2018, 39, 3128-3134.	2.2	30
27	Personalized Medicine and the Treatment of Hypertension. <i>Current Hypertension Reports</i> , 2019, 21, 13.	3.5	28
28	Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure. <i>MSystems</i> , 2021, 6, e0009521.	3.8	26
29	Human Urinary mRNA as a Biomarker of Cardiovascular Disease. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002213.	3.6	25
30	Anxiety in the “Age of Hypertension”. <i>Current Hypertension Reports</i> , 2014, 16, 486.	3.5	23
31	Clinical research using extracellular vesicles: insights from the International Society for Extracellular Vesicles 2018 Annual Meeting. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1535744.	12.2	23
32	A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension. <i>Journal of Human Hypertension</i> , 2014, 28, 3-9.	2.2	22
33	Cigarette Smoking and Subtypes of Uncontrolled Blood Pressure Among Diagnosed Hypertensive Patients: Paradoxical Associations and Implications. <i>American Journal of Hypertension</i> , 2017, 30, 602-609.	2.0	21
34	Identification and Development of Therapeutics for COVID-19. <i>MSystems</i> , 2021, 6, e0023321.	3.8	20
35	Managing hypertension during the COVID-19 pandemic. <i>Journal of Human Hypertension</i> , 2020, 34, 415-417.	2.2	19
36	Personalized medicine and treatment approaches in hypertension: current perspectives. <i>Integrated Blood Pressure Control</i> , 2016, 9, 59.	1.2	18

#	ARTICLE	IF	CITATIONS
37	For what factors should we normalize urinary extracellular mRNA biomarkers?. <i>Biomolecular Detection and Quantification</i> , 2019, 17, 100090.	7.0	16
38	Use of physicianâ€recommended nonâ€pharmacological strategies for hypertension control among hypertensive patients. <i>Journal of Clinical Hypertension</i> , 2018, 20, 518-527.	2.0	15
39	Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE) Tj ETQq1 1 0.784314 rgBT /Ove	2.0	15
40	Pandemic Pandemonium. <i>Circulation</i> , 2020, 141, 2045-2047.	1.6	15
41	Out-of-Office Blood Pressure Monitoring in 2018. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1805.	7.4	12
42	Current Status of Angiotensin Receptor Blocker Recalls. <i>Hypertension</i> , 2019, 74, 1275-1278.	2.7	12
43	Extracellular Vesicles in Essential Hypertension: Hidden Messengers. <i>Current Hypertension Reports</i> , 2020, 22, 76.	3.5	12
44	ST-segment elevation in patients presenting with COVID-19: case series. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytaa553.	0.6	12
45	Data-Sharing Models. <i>New England Journal of Medicine</i> , 2017, 376, 2305-2306.	27.0	11
46	Response by Cohen et al to Letter Regarding Article, â€œAssociation of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19â€ Circulation Research, 2020, 126, e140-e141.	4.5	11
47	Hypertension. <i>Annals of Internal Medicine</i> , 2019, 170, ITC65.	3.9	10
48	Angiotensin Receptor Blockers and the Risk of Cancer: Insights from Clinical Trials and Recent Drug Recalls. <i>Current Hypertension Reports</i> , 2020, 22, 20.	3.5	10
49	24-Hour Profiles of 11-Oxygenated C19 Steroids and 11 β -Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency. <i>Frontiers in Endocrinology</i> , 2021, 12, 751191.	3.5	10
50	Differential COVID-19 Symptoms Given Pandemic Locations, Time, and Comorbidities During the Early Pandemic. <i>Frontiers in Medicine</i> , 2022, 9, 770031.	2.6	10
51	Pollen Count and Presentation of Angiotensin-Converting Enzyme Inhibitorâ€Associated Angioedema. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2013, 1, 468-473.e4.	3.8	9
52	Arm Position During Ambulatory Blood Pressure Monitoring: A Review of the Evidence and Clinical Guidelines. <i>Journal of Clinical Hypertension</i> , 2014, 16, 225-230.	2.0	8
53	Aldosterone Synthase Promoter Polymorphism and Cardiovascular Phenotypes in a Large, Multiethnic Population-Based Study. <i>Journal of Investigative Medicine</i> , 2015, 63, 862-866.	1.6	7
54	Medicare reimbursement policy for ambulatory blood pressure monitoring: A qualitative analysis of public comments to the Centers for Medicare and Medicaid Services. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1803-1809.	2.0	6

#	ARTICLE	IF	CITATIONS
55	The Contribution of the ACCOMPLISH Trial to the Treatment of Stage 2 Hypertension. <i>Current Hypertension Reports</i> , 2014, 16, 419.	3.5	5
56	Clopidogrel prescription filling delays and cardiovascular outcomes in a pharmacy system integrating inpatient and outpatient care: Insights from the Veterans Affairs CART Program. <i>American Heart Journal</i> , 2014, 168, 340-345.	2.7	5
57	The possibility of unmeasured confounding variables in observational studies: a forgotten fact?. <i>Heart</i> , 2011, 97, 1815-1816.	2.9	4
58	Monitoring Blood Pressure Outside of the Doctor's Office. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1830.	7.4	4
59	Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities. <i>European Heart Journal</i> , 2021, 42, 697-699.	2.2	4
60	Ten Rules for Conducting Retrospective Pharmacoepidemiological Analyses: Example COVID-19 Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 700776.	3.5	4
61	Pericardial Effusion in Renal Disease: To Tap or Not to Tap. <i>Cardiology</i> , 2011, 120, 204-208.	1.4	3
62	Pharmacologic treatment of hypertension. , 2019, , 477-482.		3
63	Rigor before speculation in COVID-19 therapy. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 318, L1027-L1028.	2.9	3
64	Ontology-Based Classification and Analysis of Adverse Events Associated With the Usage of Chloroquine and Hydroxychloroquine. <i>Frontiers in Pharmacology</i> , 2022, 13, 812338.	3.5	3
65	Primary Aldosteronism. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2160-2161.	5.3	2
66	Correction for Rando et al., "Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure". <i>MSystems</i> , 2022, , e0144721.	3.8	2
67	Les effets secondaires aigus des inhibiteurs de l'enzyme de conversion de l'angiotensine dont l'angiotensine II, différents dans leur physiopathologie clinique, partagent une physiopathologie semblable. <i>Revue Française D'allergologie Et D'immunologie Clinique</i> , 2008, 48, 434-440.	0.1	1
68	Opening Opportunities With Open Data. <i>JACC: Heart Failure</i> , 2018, 6, 530-532.	4.1	1
69	Score one for the clinical trial data sharing experiment. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 567-568.	1.8	1
70	Primary Aldosteronism in the Primary Care Clinic: Rife or Rare?. <i>Endocrine Practice</i> , 2016, 22, 1350-1352.	2.1	0
71	Alternative Approaches for Lowering Blood Pressure. , 2018, , 274-279.		0
72	Strengthening a societal tie and other new initiatives for 2019. <i>Journal of Human Hypertension</i> , 2019, 33, 173-173.	2.2	0

#	ARTICLE	IF	CITATIONS
73	Total and Out-of-Pocket Expenditures on Antihypertensive Medications in the United States, 2007â€“2019. Hypertension, 2021, 78, 1662-1664.	2.7	0